Simcere Pharmac Grp Stock Operating Margin

S2P Stock  EUR 0.82  0.01  1.20%   
SIMCERE PHARMAC GRP fundamentals help investors to digest information that contributes to SIMCERE PHARMAC's financial success or failures. It also enables traders to predict the movement of SIMCERE Stock. The fundamental analysis module provides a way to measure SIMCERE PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SIMCERE PHARMAC stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SIMCERE PHARMAC GRP Company Operating Margin Analysis

SIMCERE PHARMAC's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current SIMCERE PHARMAC Operating Margin

    
  0.1 %  
Most of SIMCERE PHARMAC's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SIMCERE PHARMAC GRP is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Based on the recorded statements, SIMCERE PHARMAC GRP has an Operating Margin of 0.0982%. This is 100.28% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The operating margin for all Germany stocks is 101.78% lower than that of the firm.

SIMCERE Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SIMCERE PHARMAC's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SIMCERE PHARMAC could also be used in its relative valuation, which is a method of valuing SIMCERE PHARMAC by comparing valuation metrics of similar companies.
SIMCERE PHARMAC is currently under evaluation in operating margin category among its peers.

SIMCERE Fundamentals

About SIMCERE PHARMAC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SIMCERE PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SIMCERE PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SIMCERE PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in SIMCERE Stock

SIMCERE PHARMAC financial ratios help investors to determine whether SIMCERE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SIMCERE with respect to the benefits of owning SIMCERE PHARMAC security.